Cargando…

PB2072: CIRCULATING CD71+ MYELOID PRECURSORS IN MGUS AND MULTIPLE MYELOMA: A PROSPECTIVE SURVEY

Detalles Bibliográficos
Autores principales:	Parrinello, Nunziatina Laura, Duminuco, Andrea, Marino, Sara, Triolo, Anna, Conticello, Concetta, Del Fabro, Vittorio, Romano, Alessandra, DI Raimondo, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429661/ http://dx.doi.org/10.1097/01.HS9.0000975088.04474.77

Ejemplares similares

PB2093: OVERALL SURVIVAL IN RELAPSED-REFRACTORY MYELOMA PATIENTS DEPENDS ON CIRCULATING PLASMA CELLS QUANTITATION
por: Parrinello, Nunziatina Laura, et al.
Publicado: (2023)

PB1993: EXPRESSION OF NEO-201 MAY HELP IN THE DIFFERENTIAL DIAGNOSIS BETWEEN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
por: Duminuco, Andrea, et al.
Publicado: (2023)

PB2073: EVALUATION OF THE PLASMA METABOLOMIC PROFILE OF MGUS AND MULTIPLE MYELOMA PATIENTS
por: Ciesluk, Klaudia, et al.
Publicado: (2023)

Lenalidomide and Pomalidomide Improve Function and Induce FcγRI/CD64 in Multiple Myeloma Neutrophils
por: Romano, Alessandra, et al.
Publicado: (2021)

PB2072: EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
por: Basturk, A., et al.
Publicado: (2022)

Serum free light chains and multiple myeloma: Is it time to extend their application?
por: Markovic, Uros, et al.
Publicado: (2020)

P43 CIRCULATING CLONAL PLASMA CELLS AT START OF SALVAGE REGIMEN PROVIDE POWERFUL PROGNOSTICATION BIOMARKER IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE
por: Romano, A., et al.
Publicado: (2023)

Immunological Dysregulation in Multiple Myeloma Microenvironment
por: Romano, Alessandra, et al.
Publicado: (2014)

Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study
por: Markovic, Uros, et al.
Publicado: (2021)

PB2279: REDUCED ABSOLUTE COUNT OF MONOCYTES IN PATIENTS CARRYING HEMATOLOGICAL NEOPLASMS AND SARS-COV2 BREAKTHROUGH INFECTION
por: Romano, A., et al.
Publicado: (2022)

Salvage Therapy of Multiple Myeloma: The New Generation Drugs
por: Romano, Alessandra, et al.
Publicado: (2014)

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
por: Romano, Alessandra, et al.
Publicado: (2019)

A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?
por: Markovic, Uros, et al.
Publicado: (2019)

Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab
por: Duminuco, Andrea, et al.
Publicado: (2023)

Multiple Myeloma in 2023 Ways: From Trials to Real Life
por: Fazio, Manlio, et al.
Publicado: (2023)

High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling
por: Romano, A., et al.
Publicado: (2020)

Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study
por: Del Fabro, Vittorio, et al.
Publicado: (2023)

PB2534: SARS-COV-2 IMMUNIZATION AFTER VACCINES IN PATIENTS WITH HEMOGLOBINOPATHY: A SINGLE CENTER EXPERIENCE
por: Duminuco, Andrea, et al.
Publicado: (2023)

Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3
por: Puglisi, Fabrizio, et al.
Publicado: (2019)

Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)
por: Giallongo, Cesarina, et al.
Publicado: (2016)

Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells
por: Tibullo, Daniele, et al.
Publicado: (2015)

The effect of azacitidine therapy on the M protein of MDS patients with concomitant MGUS
por: Oka, Satoko, et al.
Publicado: (2018)

CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment
por: Giallongo, Cesarina, et al.
Publicado: (2022)

PB2107: CLINICAL MANIFESTATIONS AND EFFICACY ANALYSIS OF 71 CASES OF AIDS-RELATED LYMPHOMA
por: Liu, J., et al.
Publicado: (2022)

P852: ARGININE DEPRIVATION INDUCES ACQUISITION OF A SENESCENT PHENOTYPE AND FAVORS GENOMIC INSTABILITY IN MULTIPLE MYELOMA PLASMA CELLS
por: Romano, Alessandra, et al.
Publicado: (2023)

PB2081: CYTOGENETICS OF MULTIPLE MYELOMA IN MOROCCO
por: Moutmir, Yasmine, et al.
Publicado: (2023)

PB1702: ACTIVINA MODULATES THE MICRORNA CARGO OF EXTRACELLULAR VESICLES RELEASED BY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL) CELLS
por: Licari, Eugenia, et al.
Publicado: (2023)

How we manage smoldering multiple myeloma
por: Romano, Alessandra, et al.
Publicado: (2020)

PB1974: MULTIVARIATE SPECTRAL BIOTYPING OF EXTRAMEDULLARY MULTIPLE MYELOMA
por: Vlachová, M., et al.
Publicado: (2022)

PB1990: MULTIPLE MYELOMA IN THE ELDERLY: A MONOCENTRIC EXPERIENCE
por: Charfi, H., et al.
Publicado: (2022)

PB2278: INVESTIGATION ON THE STATUS OF INFECTION IN PATIENTS WITH MULTIPLE MYELOMA
por: Lan, D., et al.
Publicado: (2022)

PB1975: THE RESEARCH ON THE MECHANISM OF RRAD GENE IN MULTIPLE MYELOMA
por: Yi, C., et al.
Publicado: (2022)

PB1981: EFFICACY AND SAFETY OF DENOSUMAB IN PATIENTS WITH MULTIPLE MYELOMA
por: Bougherira, S., et al.
Publicado: (2022)

PB1969: FUNCTIONAL CHARACTERIZATION OF SUSCEPTIBILITY LOCI TO MULTIPLE MYELOMA
por: Shokouhi, M., et al.
Publicado: (2022)

PB1754: HOMOZYGOUS DELETION OF ETV6: EARLY T-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA OR PRECURSOR T-LYMPHOBLASTIC LYMPHOMA
por: Álvarez, Miguel Ángel Perera, et al.
Publicado: (2023)

Myeloma precursor disease (MGUS) among rescue and recovery workers exposed to the World Trade Center disaster
por: Zeig-Owens, Rachel, et al.
Publicado: (2022)

Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies
por: Palumbo, Giuseppe Alberto, et al.
Publicado: (2019)

TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma
por: Giallongo, Cesarina, et al.
Publicado: (2019)

PB1966: HEMOPOIETIC NICHE IMPAIRMENT IN TREATED MULTIPLE MYELOMA PATIENTS
por: Semenova, N. Y., et al.
Publicado: (2022)

PB2086: SIMULTANEOUS DIAGNOSIS OF MULTIPLE MYELOMA AND MYELODYSPLASIA: CASE REPORT.
por: Benabed, Khaled, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6fvdkuaoif531q05i5v0d665mi